VTEU COVID-19 Trials

Two randomized, placebo-controlled clinical trials funded by the NIH are expanding enrollment to include the VTEU at NYU to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19.

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. New England Journal of Medicine

An investigational vaccine designed to protect against COVID-19 resulted in production of both binding and neutralizing antibodies in healthy adult volunteers, according to interim results of an ongoing phase 1 trial published in the NEJM. The Phase 1 trial was led and supported by IDCRC sites.

The NIAID-sponsored, Infectious Diseases Clinical Research Consortium (IDCRC) and the nation’s Vaccine Trials and Evaluation Units (VTEUs) enrolled a quarter of all patients in this international study.

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

Logos and headshots of the leadership group
VTEUs
Logos and headshots for each VTEU


NIAID Division of Microbiology and Infectious Diseases (DMID)